Table 1. Clinico-pathological data and perioperative chemotherapy schedules for patients treated by radical cystectomy and adjuvant radiotherapy.
| Parameters | Patients N (%) |
|---|---|
| Median age at diagnosis in years (range) | 66.3 (45–84) |
| ECOG PS* | |
| 0 | 21 (36.8) |
| 1 | 35 (61.4) |
| 2 | 1 (1.8) |
| Male | 47 (82.5) |
| Female | 10 (17.5) |
| Stage T TURB | |
| T1 | 4 (7) |
| T2 | 47 (82.5) |
| T3 | 2 (3.5) |
| T4 | 4 (7) |
| Stage N before radical cystectomy | |
| N0 | 39 (68.4) |
| N1 | 4 (7) |
| N2 | 1 (1.8) |
| N3 | 1 (1.8) |
| Nx | 12 (21.1) |
| Multifocal lesions at TURB | |
| Yes | 6 (10.5) |
| No | 39 (68.4) |
| Unknown | 12 (21.1) |
| Association with carcinoma in situ at TURB | |
| Yes | 7 (12.3) |
| No | 30 (52.6) |
| Unknown | 20 (35.1) |
| Adjuvant CT regimen | 27 (47.4) |
| GC | 9 (15.8) |
| GCb | 5 (8.8) |
| SD-MVAC | |
| Median number delivered cycles (SD) | 6 (1.02) |
| Neoadjuvant CT regimen, No (%) | |
| DD-MAVC | 2 (3.5) |
| SD-MVAC | 2 (3.5) |
| GC | 3 (5.3) |
| Median number of delivered cycles (SD) | 4 (0.64) |
*Eastern Cooperative Oncology Group (ECOG); PS: Performance status; TURB: Transurethral resection of bladder; CT: chemotherapy; GC: gemcitabine-cisplatin; GCb: gemcitabine-carboplatin; MVAC: Methotrexate-vinblastine-adriamycine-cisplatin; DD: dose-dense; SD: standard; RC: radical cystectomy; SD: standard deviation